Review explores ncRNAs' influence on autophagy in Alzheimer's Disease, suggesting new therapeutic targets.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and one of the leading causes of dementia, imposing a profound burden on patients, families, and healthcare systems worldwide. Autophagy, an evolutionarily conserved lysosomal degradation pathway critical for maintaining cellular homeostasis, removes damaged organelles and misfolded proteins, thereby preserving metabolic balance and enabling intracellular biomolecule recycling. Growing evidence indicates that dysfunctional autophagy contributes to AD pathogenesis. Concurrently, non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), have emerged as pivotal regulators of AD pathology, particularly through mechanisms involving autophagy. These ncRNAs not only play a role in disease progression but also represent promising molecular targets for therapeutic intervention via autophagy modulation. This review systematically explores the regulatory networks through which ncRNAs influence autophagy in AD, with the goal of identifying potential therapeutic targets and offering a conceptual framework to guide clinical translation. • The "ncRNA-autophagy axis" drives a vicious cycle of Aβ/tau pathology in AD. • ncRNAs exhibit stage- and cell type-specific regulatory roles during autophagic flux. • miR-34a, miR-155, and miR-17 are prioritized as high-potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: